BIMI International Medical Inc.
Find Ratings ReportsBIMI INTERNATIONAL MEDCL INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. BIMI INTERNATIONAL MEDCL INC has very weak liquidity. Currently, the Quick Ratio is 0.26 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 11.14% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 2.52 | 4.93 |
EBITDA ($mil) | 0.0 | 0.0 |
EBIT ($mil) | -3.15 | -2.41 |
Net Income ($mil) | -3.13 | -3.88 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 0.99 | 1.05 |
Total Assets ($mil) | 35.04 | 33.0 |
Total Debt ($mil) | 4.47 | 12.62 |
Equity ($mil) | 8.71 | 9.8 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 4.6 | 14.25 |
EBITDA Margin | 0.0 | 0.0 |
Operating Margin | -124.85 | -48.91 |
Sales Turnover | 0.36 | 0.37 |
Return on Assets | -29.99 | -129.8 |
Return on Equity | -120.81 | -427.48 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 1.21 | 0.92 |
Debt/Capital | 0.34 | 0.56 |
Interest Expense | 0.04 | 0.0 |
Interest Coverage | -90.0 | 0.0 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 6.67 | 3.84 |
Div / share | 0.0 | 0.0 |
EPS | -0.47 | -1.3 |
Book value / share | 1.3 | 2.55 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 32282.0 | 17842.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.96 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 20.75. The price-to-sales ratio is well below the S&P 500 average, but well above the subsector average. The valuation analysis reveals that, BIMI INTERNATIONAL MEDCL INC seems to be trading at a premium to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIMI NM | Peers 23.56 | BIMI NM | Peers 12.26 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. BIMI's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BIMI's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
BIMI NA | Peers 14.94 | BIMI NA | Peers 1.03 | |||||||||||||||||||||
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential. Ratio not available. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
BIMI 1.96 | Peers 20.75 | BIMI 94.11 | Peers 39.44 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BIMI is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. BIMI is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
BIMI 1.35 | Peers 0.57 | BIMI 2.25 | Peers 2.59 | |||||||||||||||||||||
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BIMI is trading at a significant premium to its subsector. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. BIMI trails its peers on the basis of sales growth. |
|||||||||||||||||||||||